pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,491
stories
15d
STAT+: Momentum is building for a big change to how doctors get paid
stat
15d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
15d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
15d
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
fiercebiotech
15d
Recon: Adcomm backs Grail’s cancer test; Lilly, China’s InnoCare sign $3.35B deal
raps
15d
STAT+: Nominee to lead FDA aims to speed up medical research, combat China’s rise
stat
15d
STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
stat
15d
FDA adcomm votes in favor of benefit-risk of Grail’s cancer test
endpoints
15d
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
15d
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
15d
New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption
fiercebiotech
15d
STAT+: Flagship gets a Pentagon contract
stat
15d
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
16d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
16d
STAT+: A private equity-owned hospital chain is becoming a nonprofit. Is it just a bailout for investors?
stat
16d
Opinion: Mentally ill women deserve more support to have children
stat
16d
STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
stat
16d
9 companies hiring in Pennsylvania now
biospace
16d
China’s surging biotech sector represents both competition and lifeline for the US
biospace
16d
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
16d
Compass vows to press on with FDA application despite new trial request
biospace
16d
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
16d
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
endpoints
16d
‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant?
fiercebiotech
16d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
16d
2026 IPO blitz continues with 4 new biotech filings
biospace
16d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
16d
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
16d
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
16d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
← prev
page 6 of 50
next →
